These are the stocks posting the largest moves before the bell.Market Insiderread more
The Fed cut interest rates by a quarter point, but it also reaffirmed its rate cut was meant to serve as insurance for the economy.Market Insiderread more
Investors are asking how the world's third-largest defense spender could have left itself so vulnerable and what that means for the future.Politicsread more
The presidential campaign is "going to be very tough," the former chief White House strategist.Politicsread more
Huawei launched a new 5G flagship smartphone lineup Thursday without pre-installed Google-licensed apps as the Chinese tech giant faces fallout from a U.S. blacklist earlier...Technologyread more
Initially introduced in March 2018, the "Worker Dividend Act" requires firms to distribute the value of its stock buybacks dollar-for-dollar.2020 Electionsread more
The data pointed to strong labor market conditions that should continue to support a moderately growing economy.Economyread more
Warren Buffet and Jamie Dimon penned an attack on quarterly guidance and the short-term shareholder mindset last year, and support has followed from the Business Roundtable....Evolveread more
Here are the biggest calls on Wall Street on ThursdayInvestingread more
A Belgian F-16 fighter jet crashed on a road in western France and one of its pilots is hanging from a high-voltage electricity line after his parachute got caught.Aerospace & Defenseread more
Valeant Pharmaceuticals International new CEO, Joseph Papa, met with shareholders Tuesday at the company's annual meeting, outlining his stabilization plan to rebuild the company's reputation amid accusations of accounting abnormalities, price gouging and channel stuffing.
Papa, who was named CEO in April, said the company has been "a distracted organization," but he is focused on paying off $1.7 billion of its $30 billion debt by 2016.
"If we can sell some of those noncore assets to pay off the debts, it will allow us to pay down our additional debt," he told shareholders.
This means for the moment the company will be looking to sell businesses rather than make acquisitions as it has done in recent years. Valeant will likely keep is Bausch & Lomb and Salix businesses as well as its dermatology, gastrointestinal and consumer products operations.
The dermatology business, however, faces significant challenges as sales have fallen significantly in recent months. But Papa expressed some confidence in the business.
"We have the leading portfolio of dermatology brands and the strongest new product pipeline in dermatology," he said.
Valeant's meeting in Laval, Quebec, comes as the company's stock has plunged more than 90 percent in the past year, weighed down by concerns over its acquisition binge of recent years, use of a specialty pharmacy and backlash over massive price increases for some drugs.
On April 25, Valeant tapped Papa, who has 35 years experience in the pharmaceutical industry, for the role of chairman and CEO, succeeding Michael Pearson.
Among questions from shareholders about the state of the company, one investor asked Papa about how the embattled company plans to handle its government inquires on its drug pricing.
Papa said the company plans to deal with the matter as quickly as possible and "whatever we face we are going to cooperate and we are going to deal with them appropriately."
Shares of Valeant slipped slightly after the meeting, falling less than 1 percent.